Citations

Clear

7552 citation(s) found for "Ku, Matthew".

Postoperative Implementation of Virtual Reality and Wearable Devices: Opportunities and Challenges
Pandrangi, Vivek C. , Araujo, Ana V. , Buncke, Michelle , Olson, Brennan , Jorizzo, Matthew , Said‐Al‐Naief, Nasser, Sanusi, Olabisi , Ciporen, Jeremy , Shindo, Maisie L., Schindler, Joshua S. , Colaianni, C. Alessandra , Flint, Paul W., Wax, Mark K. , Li, Ryan J. , Clayburgh, Daniel , Wax, Mark K , Geltzeiler, Mathew , Olson, Brennan G , Andersen, Peter E. , Geltzeiler, Mathew

Mayo Clinic

The Laryngoscope | January 3, 2025 | Volume: 135 | Issue: 6 | Pages: 2044-2050

10.1002/lary.31989 | PMID 39749757 Get It

ObjectiveTo examine implementation of virtual reality (VR) and Fitbit wearable activity devices in postoperative recovery.MethodsThis was a prospective, 4‐arm, randomized controlled trial of patients undergoing inpatient head and neck surgery at a tertiary academic center from November 2021 to July 2022. Patients were randomized to Control, VR, Fitbit, or combined VR + Fitbit groups. Patients in the VR groups were brought VR headsets to use throughout each day, and patients in the Fitbit groups wore Fitbit devices and were encouraged to achieve 2,000 daily steps. The primary outcome was average daily opioid use, measured as milligram morphine equivalents (MME).ResultsThere were 80 patients included. The majority of patients were male (68.8%), and mean age was 58.8 ± 14.4 years. Only the combined VR + Fitbit cohort was associated with reduced average daily opioid use (VR + Fitbit: 8.8 [20.6] MME vs. Control: 26.4 [37.4] MME, p = 0.02). Patients in intervention groups also had higher hospital satisfaction (p = 0.02). VR was utilized 26% of the time it was provided, with mean use time of 23.8 ± 7.8 min. Mean post‐VR subjective pain reduction was 1.0 ± 1.3, and there were three mild adverse events of neck or nasal discomfort. Among the Fitbit groups, there were no adverse events and daily step counts ≥2,000 steps were achieved 45% of the time.ConclusionImplementation of VR and wearable activity devices in postoperative recovery appears well tolerated and may facilitate further development of Enhanced Recovery After Surgery (ERAS) protocols, though there are challenges to maximizing device usage.Level of Evidence2 Laryngoscope, 135:2044–2050, 2025
Contemporary nonsurgical management of Peyronie's disease
Pinkhasov, Alexandr, Tentis, Elise, Ziegelmann, Matthew , Pinkhasov, Alexandr M, Yang, David Y.

Mayo Clinic

Current Opinion in Urology | January 2, 2025 | Volume: 35 | Issue: 2 | Pages: 135-141

10.1097/mou.0000000000001255 | PMID 39744754 Get It

Purpose of review Peyronie's disease characterizes a condition in which there is angular curvature of the penis. We know that the most patients with Peyronie's disease will not have spontaneous resolution of their penile curvature. As such, patients who desire treatment can elect for either surgical or nonsurgical therapy. Herein, we discuss the contemporary nonsurgical management options for Peyronie's disease. Recent findings Nonsurgical management options for Peyronie's disease include oral therapy, intra-lesional injections, and penile traction therapy. At the time of this review, there is essentially no high-level evidence demonstrating any benefit for oral therapy. Penile traction therapy has evolved over the past decade with second-generation devices demonstrating strong efficacy and more convenient treatment regimens. Intra-lesional options include collagenase Clostridium histolyticum (CCH), verapamil, and interferon alpha-2b. The IMPRESS trial garnered the strongest level of evidence (two randomized, double-blind, placebo-controlled trials) to support the safety and efficacy of CCH. Verapamil is an option supported by several urological societies; however, the evidence supporting its efficacy is inconsistent between several notable series and randomized studies. IFN alpha 2b can produce modest improvement in curvature, however, is not available for use in North America. Summary Herein, we will discuss notable advances in nonsurgical management of Peyronie's disease.
Modular dual-mobility constructs outperformed large femoral heads in 299 revision total hip arthroplasties at mid-term follow-up
Carender, Christopher N. , Fruth, Kristin M. , Taunton, Michael J. , Pagnano, Mark W., Taunton, Michael J , Bedard, Nicholas A. , Pagnano, Mark W. , Abdel, Matthew P.

Mayo Clinic

The Bone & Joint Journal | January 1, 2025 | Volume: 107-B | Issue: 1 | Pages: 58-64

10.1302/0301-620x.107b1.bjj-2024-0170.r1 | PMID 39743935 Get It

AimsThe purpose of this study was to directly compare the Modular Dual Mobility (MDM) Mobile Bearing Hip System (Stryker, USA) and large femoral heads (LFHs) in revision total hip arthroplasties (THAs) at mid-term follow-up, with specific emphasis on survival free of re-revision for dislocation, any re-revision, dislocation, and the risk of metal-related complications.MethodsWe identified 299 revision THAs performed at a single tertiary care academic institution from March 2011 to July 2014. Aseptic loosening of the acetabular component (n = 65), dislocation (n = 58), and reimplantation as part of a two-stage exchange protocol (n = 57) were the most common reasons for index revision. MDM constructs were used in 123 cases, and LFHs were used in 176 cases. Mean age was 66 years (28 to 93), mean BMI was 31 kg/m2 (18 to 55), and 45% (n = 136) were female. Mean follow-up was seven years (2 to 12).ResultsThe ten-year survival free of re-revision for dislocation was 99% (95% CI 95 to 100) in the MDM cohort and 91% (95% CI 84 to 96) in the LFH cohort, with a significantly increased risk of re-revision for dislocation in the LFH cohort (HR 7.1 (95% CI 1.3 to 40.8); p = 0.023). The ten-year survival free of any re-revision was 92% (95% CI 82 to 99%) in the MDM cohort and 84% (95% CI 74 to 90) in the LFH cohort with a significantly increased risk of any re-revision in the LFH cohort (HR 2.6 (95% CI 1.1 to 5.9); p = 0.024). The ten-year survival free of any dislocation was 95% (95% CI 85 to 99) in the MDM cohort and 87% (95% CI 78 to 92) in the LFH cohort with a significantly increased risk of any dislocation in the LFH cohort (HR 2.7 (95% CI 1.1 to 6.3); p = 0.028). There were no re-revisions or reoperations for metallosis or corrosion in the MDM cohort.ConclusionIn this head-to-head comparison, revision THAs with a MDM construct safely and effectively lowered the risk of re-revision for dislocation, any re-revision, and any dislocation compared to LFH at mid-term follow-up. There were no re-revisions or reoperations for metallosis or corrosion in the MDM cohort.Cite this article: Bone Joint J 2025;107-B(1):58–64.
Do Factors Influencing Acceptance of Kidney Stone Formers as Donors Predict Subsequent Stone Events?
Keddis, Mira T. , Howard, Matthew R., Zhang, Nan , Quillen, Jaxon , D’Costa, Matthew R. , Khamash, Hasan , Porter, Ivan E. , Stern, Karen , Quillen, Jaxon K, Khamash, Hasan A, Jadlowiec, Caroline , Wadei, Hani M , Porter, Ivan , D'Costa, Matthew , Stern, Karen L , Jadlowiec, Caroline C. , Wadei, Hani M. , Rule, Andrew D.

Mayo Clinic

Clinical Transplantation | December 31, 2024 | Volume: 39 | Issue: 1 | Pages: No page available

10.1111/ctr.70069 | PMID 39737621 Get It

ABSTRACTPurposeThis study aimed to assess whether kidney stone burden and risk factors at the time of kidney donor evaluation were associated with a symptomatic stone event post‐donor evaluation.MethodsWe identified adults evaluated at Mayo Clinic (two sites) (2000–2011) for living kidney donation and had either a personal history or radiological evidence of kidney stone disease. We analyzed demographics, stone risk factors, stone number/size, and the committee's donation decision and reasons. A follow‐up survey (2022–2023) assessed post‐evaluation symptomatic kidney stones and related morbidity.ResultsAmong 412 potential donors with kidney stone disease, 258 donated, 75 did not donate due to kidney stones, and 79 did not donate for other reasons. Multivariable analysis showed that candidates not donating due to stones had higher body mass index (BMI), prior symptomatic kidney stones, multiple stones on imaging, bilateral kidney stones, and diameter of largest stone ≥3 mm. Of 147 who completed the survey, 26 (18%) had a symptomatic kidney stone post‐donor evaluation. Younger age (p = 0.031) and multiple stones on imaging (p = 0.02) were significant predictors of post‐evaluation symptomatic stones regardless of donation status (p = 0.41).ConclusionsStone burden on imaging and prior symptomatic stone events were associated with not donating. Younger age and stone burden on imaging were the primary risk factors for a symptomatic kidney stone event after donor evaluation.
Real‐Time 2D Phase‐Contrast MRI to Assess Cardiac‐ and Respiratory‐Driven CSF Movement in Normal Pressure Hydrocephalus
Karki, Pragalv , Murphy, Matthew C. , Ganji, Sandeep , Gunter, Jeffrey L. , Graff‐Radford, Jonathan, Cutsforth‐Gregory, Jeremy K. , Elder, Benjamin D. , Jack, Clifford R. , Jack, Clifford R , Ganji, Sandeep K , Graff‐Radford, Jonathan , Jones, David T. , Botha, Hugo , Huston, John , Cogswell, Petrice M.

Mayo Clinic

Journal of Neuroimaging | December 31, 2024 | Volume: 35 | Issue: 1 | Pages: No page available

10.1111/jon.70000 | PMID 39737803 Get It

ABSTRACT Background and Purpose In idiopathic normal pressure hydrocephalus (iNPH) patients, cerebrospinal fluid (CSF) flow is typically evaluated with a cardiac‐gated two‐dimensional (2D) phase‐contrast (PC) MRI through the cerebral aqueduct. This approach is limited by the evaluation of a single location and does not account for respiration effects on flow. In this study, we quantified the cardiac and respiratory contributions to CSF movement at multiple intracranial locations using a real‐time 2D PC‐MRI and evaluated the diagnostic value of CSF dynamics biomarkers in classifying iNPH patients. Methods This study included 37 participants: 16 iNPH, 10 Alzheimer's disease (AD), and 11 cognitively unimpaired (CU) controls. Anatomical and real‐time (non‐gated) PC images were acquired in a 3T Philips scanner. CSF flow was assessed at the foramen magnum, fourth ventricle, Sylvian fissure, lateral ventricle, and cerebral aqueduct. We calculated three CSF dynamics biomarkers: mean velocity amplitude, cardiac signal power, and respiratory signal power. Biomarkers from each location were evaluated for classifying iNPH versus AD and CU using support vector machine (SVM). A p ‐value of 0.05 or less was considered statistically significant. Results The velocity amplitude and cardiac signal power were significantly reduced in iNPH compared to CU ( p < 0.005) and AD ( p < 0.05) at the lateral ventricle. The SVM model using biomarkers from the lateral ventricle performed significantly better at classifying iNPH than the other locations in terms of accuracy ( p < 0.005) and diagnostic odds ratio ( p < 0.05). Conclusion Evaluation of CSF movement beyond the cerebral aqueduct may aid in identifying patients with and understanding the pathophysiology of iNPH.
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study
Topp, Max S. , Matasar, Matthew J. , Allan, John N. , Ansell, Stephen M. , Barnes, Jeffrey A. , Arnason, Jon , Michot, Jean‐Marie , Goldschmidt, Neta , Abadi, Uri , Avivi, I., Cheng, Yuan , Flink, Dina M., Brouwer‐Visser, Jurriaan , Chaudhry, Aafia, Ambati, Srikanth, Crombie, Jennifer L. , Matasar, Matthew , O’Brien, Susan , Zhu, Min , Mohamed, Hesham

Mayo Clinic

Blood | December 30, 2024 | Volume: 145 | Issue: 14 | Pages: 1498-1509

10.1182/blood.2024027044 | PMID 39786390 Get It

Abstract Patients with relapsed/refractory diffuse large B-cell lymphoma progressing after chimeric antigen receptor T-cell (CAR-T) therapy have dismal outcomes. The prespecified post–CAR-T expansion cohort of the ELM-1 study investigated the efficacy and safety of odronextamab, a CD20×CD3 bispecific antibody, in patients with disease progression after CAR-Ts. Sixty patients received IV odronextamab weekly for 4 cycles followed by maintenance until progression. The primary end point was objective response rate (ORR) by independent central review. The median number of prior lines of therapy was 3 (range, 2-9), 71.7% were refractory to CAR-Ts, and 48.3% relapsed within 90 days of CAR-T therapy. After a median follow-up of 16.2 months, ORR and complete response (CR) rate were 48.3% and 31.7%, respectively. Responses were similar across prior CAR-T products and time to relapse on CAR-T therapy. Median duration of response was 14.8 months and median duration of CR was not reached. Median progression-free survival and overall survival were 4.8 and 10.2 months, respectively. The most common treatment-emergent adverse event was cytokine release syndrome (48.3%; no grade ≥3 events). No cases of immune effector cell–associated neurotoxicity syndrome were reported. Grade ≥3 infections occurred in 12 patients (20.0%), 2 of which were COVID-19. Odronextamab monotherapy demonstrated encouraging efficacy and generally manageable safety, supporting its potential as an off-the-shelf option for patients after CAR-T therapy. This trial was registered at www.clinicaltrials.gov as #NCT02290951.
A field resource for the glioma cerebrospinal fluid proteome: Impacts of resection and location on biomarker discovery
Riviere-Cazaux, Cécile , Warrington, Arthur E. , Hoplin, Matthew D. , Andersen, Katherine M., Malik, Noor , Palmer, Elizabeth, Dasari, Surendra , Munoz-Casabella, Amanda , Ikram, Samar, Jusué-Torres, Ignacio , Meyer, Fredric B. , Kizilbash, Sani H. , Campian, Jian , Palmer, Elizabeth A, Carlstrom, Lucas P. , Sarkaria, Jann N , Van Gompel, Jamie J , Kizilbash, Sani H , Jusue-Torres, Ignacio , Malik, Noor , Michor, Franziska , Ghadimi, Keyvan , Himes, Benjamin , Sarkaria, Jann N. , Gompel, Jamie J. Van , Sener, Uğur , Parney, Ian F. , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | December 27, 2024 | Volume: 27 | Issue: 4 | Pages: 948-962

10.1093/neuonc/noae277 | PMID 39786485 Get It

Abstract Background While serial sampling of glioma tissue is rarely performed prior to recurrence, cerebrospinal fluid (CSF) is an underutilized longitudinal source of candidate glioma biomarkers for understanding therapeutic impacts. However, the impact of key variables to consider in longitudinal CSF samples for monitoring biomarker discovery, including anatomical location and post-surgical changes, remains unknown. Methods Aptamer-based proteomics was performed on 147 CSF samples from 74 patients; 71 of whom had grade 2–4 astrocytomas or grade 2–3 oligodendrogliomas. This included pre- versus post-resection intracranial CSF samples obtained at early (1–16 days; n = 20 patients) or delayed (86–153 days; n = 11 patients) time points for patients with glioma. Paired lumbar versus intracranial glioma CSF samples were also obtained (n = 14 patients). Results Significant differences were identified in the CSF proteome between lumbar, subarachnoid, and ventricular CSF in patients with gliomas. Importantly, we found that resection had a significant, evolving longitudinal impact on the CSF proteome, with distinct sets of proteins present at different time points since resection. Our analysis of serial intracranial CSF samples suggests the early potential for disease monitoring and evaluation of pharmacodynamic impact of targeted therapies, such as bevacizumab and immunotherapies. Conclusions The intracranial glioma CSF proteome serves as a rich and dynamic reservoir of potential biomarkers that can be used to evaluate the effects of resection and other therapies over time. All data within this study, including detailed individual clinical annotations, are shared as a resource for the neuro-oncology community to collectively address these unanswered questions and further understand glioma biology through CSF proteomics.
Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: A Children’s Oncology Group Bone Tumor Committee Consensus Statement
Dietz, Matthew S. , Al‐Ibraheemi, Alyaa , Craig, Brian T. , Dasgupta, Roshni, Geller, David S. , Shulman, David S. , Whiteway, Susan L. , Slotkin, Emily K. , Albert, Catherine M. , Montgomery, Nicole I. , Sandberg, Jesse K. , Grier, Holcombe E. , Krailo, Mark , Isakoff, Michael S. , Rubin, Elyssa, Lawlor, Elizabeth R. , DuBois, Steven G. , Grohar, Patrick J. , Janeway, Katherine A. , Roberts, Ryan D. , Dasgupta, Roshni , Ahmed, Safia K. , Dasgupta, Roshni , Roberts, Ryan D , Davis, Jessica L. , Hawkins, C. Matthew , Cohen‐Gogo, Sarah , Gupta, Ajay Kumar , Heske, Christine M. , Indelicato, Daniel J. , Mascarenhas, Leo , Binitie, Odion , Reed, Damon R. , Bailey, Kelly M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 27, 2024 | Volume: 23 | Issue: 1 | Pages: No page available

10.6004/jnccn.2024.7063 | PMID 39729709 Get It

Trends in diagnostic biopsy sample collection approaches for primary bone sarcomas have shifted in the past 2 decades. Although open/incisional biopsies used to be the predominant approach to obtain diagnostic material for Ewing sarcoma and osteosarcoma, image-guided core needle biopsies have increased in frequency and are safe for patients. These procedures are less invasive and reduce recovery times but have potential limitations. The quantity and quality of tissue obtained through these procedures vary between institutions. Acquired viable tissue volumes can be low, limiting the conduct of downstream expanded clinical workup, molecular analyses, and research. Patients with advanced Ewing sarcoma and osteosarcoma continue to have overall poor outcomes despite dose-intensive cytotoxic chemotherapy. The biology of treatment resistance is not currently well understood, partly due to limited availability of relevant tissue to study. There is a need for access to quality tumor specimens for molecular and other analyses to identify high-risk tumor subsets and drive discovery to improve patient outcomes. Given broad variability in bone tumor tissue procurement and processing across member institutions, the Children’s Oncology Group Bone Tumor Committee convened a multidisciplinary group of experts to outline the current and near-future tissue needs for optimal clinical care and access to research platforms. The goal of this working group was to provide high-level guidance on biopsy practices that safely meet these evolving needs. Harmonizing tissue collection practices is paramount to improving the care of children, adolescents, and young adults diagnosed with Ewing sarcoma and osteosarcoma.
Associations of blood pressure with white matter hyperintensities later in life; influence of short-term menopausal hormone therapy
Kara, Firat , Tosakulwong, Nirubol , Lesnick, Timothy G. , Fought, Angela J. , Kendell-Thomas, June, Kapoor, Ekta , Faubion, Laura L. , Fields, Julie A. , Min, Hoon‐Ki , Lowe, Val J. , Jack, Clifford R. , Bailey, Kent R. , James, Taryn T. , Løbo, Rogerio A. , Pal, Lubna, Hammers, Dustin B. , Cedars, Marcelle I. , Miller, Virginia M. , Harman, S. Mitchell , Gleason, Carey E. , Kantarci, Kejal , Pal, Lubna , Kantarci, Kejal , Min, Hoon-Ki Paul , Jack, Clifford R , Kara, Firat , Kapoor, Ekta , Schwarz, Christopher G. , Senjem, Matthew L. , Manson, JoAnn E. , Hammers, Dustin B , Malek‐Ahmadi, Michael , Naftolin, Frederick , Santoro, Nanette F. , Dowling, N. Maritza

Mayo Clinic

Menopause | December 27, 2024 | Volume: 32 | Issue: 1 | Pages: 12-22

10.1097/gme.0000000000002481 | PMID 39729067 Get It

Abstract Objective To assess the association of systolic and diastolic blood pressure (SBP and DBP) in recently menopausal women with white matter hyperintensity (WMH) volume later in life and determine whether short-term menopausal hormone therapy (mHT) modifies these associations. Methods Kronos Early Estrogen Prevention Study (KEEPS) was a multicenter, randomized, double-blinded, placebo-controlled 4-year mHT trial (oral conjugated equine estrogens or transdermal 17β-estradiol). KEEPS continuation was an observational follow-up of the participants 10 years after the end of mHT. The associations between KEEPS baseline blood pressure (BP) with KEEPS continuation WMH volume were examined adjusting for covariates in model 1 (age, total intracranial volume, study site, mHT type) and model 2 (additionally conventional CVD risk factors). Interaction terms (BP × mHT type) were added into the linear regression models. Results The mean ± SD ages of participants were 53 (±2) years at KEEPS baseline and 67 (±2) years at KEEPS continuation. Elevated BP at KEEPS baseline was associated with greater WMH volume measured 14 years later (model 1: SBP: β = 0.01 [95% CI, 0.001‐0.01] and DBP: β = 0.01 [95% CI, 0.003‐0.03]) and after additionally adjusting for CVD risk factors (model 2). We did not find any evidence that mHT versus placebo modified these associations. Topographically, higher BP was associated with greater periventricular WMH in the frontal and parietal lobes. Conclusion Our findings suggest the importance of maintaining normal BP in recently postmenopausal women with low CVD risk, irrespective of short-term mHT usage, to potentially reduce the risk of WMH later in life.
Renal Juxtaglomerular Cell Tumors Exhibit Distinct Genomic and Epigenomic Features and Lack Recurrent Gene Fusions
Martínek, Petr , Mezencev, Roman , Gupta, Sounak , Wasco, Matthew J., Mohanty, Sambit K. , Cañete‐Portillo, Sofía , Aron, Manju , Kandukuri, Shivani , Lobo, João , Barkan, Güliz A. , Kılıç, İrem , Straková-Peteříková, Andrea, Ulbright, Thomas M. , Michalova, Kvetoslava , Williamson, Sean R. , Magi‐Galluzzi, Cristina , Pivovarčíková, Kristýna , Michal, Michael , Acosta, Andrés , Lobo, João

Mayo Clinic

American Journal of Surgical Pathology | December 27, 2024 | Volume: 49 | Issue: 3 | Pages: 217-226

10.1097/pas.0000000000002344 | PMID 39726250 Get It

Juxtaglomerular cell tumor (JxGCT) is a rare type of renal neoplasm demonstrating morphologic overlap with some mesenchymal tumors such as glomus tumor (GT) and solitary fibrous tumor (SFT). Its oncogenic drivers remain elusive, and only a few cases have been analyzed with modern molecular techniques. In prior studies, loss of chromosomes 9 and 11 appeared to be recurrent. Recently, whole-genome analysis identified alterations involving genes of MAPK-RAS pathway in a subset, but no major pathogenic alterations have been discovered in prior whole transcriptome analyses. Considering the limited understanding of the molecular features of JxGCTs, we sought to assess a collaborative series with a multiomic approach to further define the molecular characteristics of this entity. Fifteen tumors morphologically compatible with JxGCTs were evaluated using immunohistochemistry for renin, single-nucleotide polymorphism array (SNP), low-pass whole-genome sequencing, and RNA sequencing (fusion assay). In addition, methylation analysis comparing JxGCT, GT, and SFT was performed. All cases tested with renin (n=11) showed positive staining. Multiple chromosomal abnormalities were identified in all cases analyzed (n=8), with gains of chromosomes 1p, 10, 17, and 19 and losses of chromosomes 9, 11, and 21 being recurrent. A pathogenic HRAS mutation was identified in one case as part of the SNP array analysis. Thirteen tumors were analyzed by RNA sequencing, with 2 revealing in-frame gene fusions: TFG::GPR128 (interpreted as stochastic) and NAB2::STAT6. The latter, originally diagnosed as JxGCT, was reclassified as SFT and excluded from the series. No fusions were detected in the remaining 11 cases; of note, no case harbored NOTCH fusions previously described in GT. Genomic methylation analysis showed that JxGCT, GT, and SFT form separate clusters, confirming that JxGCT represents a distinct entity (ie, different from GT). The results of our study show that JxGCTs are a distinct tumor type with a recurrent pattern of chromosomal imbalances that may play a role in oncogenesis, with MAPK-RAS pathway activation being likely a driver in a relatively small subset.